Assembly Biosciences Enters Material Agreement
Ticker: ASMB · Form: 8-K · Filed: Jun 18, 2024 · CIK: 1426800
| Field | Detail |
|---|---|
| Company | Assembly Biosciences, INC. (ASMB) |
| Form Type | 8-K |
| Filed Date | Jun 18, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.001, $15.46, $17.00, $9.8 m, $2.8 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing
Related Tickers: ASMB
TL;DR
ASMB signed a big deal, details TBD.
AI Summary
Assembly Biosciences, Inc. announced on June 16, 2024, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. Specific details regarding the agreement, sales, or financial figures were not provided in this initial filing.
Why It Matters
This filing indicates a significant business development for Assembly Biosciences, potentially involving new partnerships, acquisitions, or financing that could impact its future operations and stock value.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could be positive or negative depending on the undisclosed terms, introducing uncertainty.
Key Players & Entities
- Assembly Biosciences, Inc. (company) — Registrant
- June 16, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-35005 (identifier) — Commission File Number
- Two Tower Place, 7th Floor, South San Francisco, California 94080 (address) — Principal Executive Offices
FAQ
What is the nature of the Material Definitive Agreement entered into by Assembly Biosciences?
The filing does not specify the nature of the Material Definitive Agreement, only that one was entered into on June 16, 2024.
When did Assembly Biosciences file this 8-K report?
The 8-K report was filed on June 18, 2024.
What is the Commission File Number for Assembly Biosciences?
The Commission File Number for Assembly Biosciences is 001-35005.
What are the principal executive offices of Assembly Biosciences?
The principal executive offices are located at Two Tower Place, 7th Floor, South San Francisco, California 94080.
What other items are reported in this 8-K filing besides the material agreement?
This 8-K filing also reports on Unregistered Sales of Equity Securities and includes Financial Statements and Exhibits.
Filing Stats: 1,838 words · 7 min read · ~6 pages · Grade level 11.9 · Accepted 2024-06-18 16:07:31
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 ASMB The Nasdaq Global Select Marke
- $15.46 — re sold at a combined offering price of $15.46. The Registered Warrant has an exerci
- $17.00 — Warrant has an exercise price equal to $17.00 per share, became immediately exercisab
- $9.8 m — tered Direct Offering are approximately $9.8 million, before deducting offering expens
- $2.8 m — the Private Placement are approximately $2.8 million, before deducting offering expens
Filing Documents
- d852840d8k.htm (8-K) — 42KB
- d852840dex41.htm (EX-4.1) — 83KB
- d852840dex42.htm (EX-4.2) — 86KB
- d852840dex51.htm (EX-5.1) — 25KB
- d852840dex101.htm (EX-10.1) — 117KB
- d852840dex102.htm (EX-10.2) — 136KB
- d852840dex103.htm (EX-10.3) — 17KB
- d852840dex104.htm (EX-10.4) — 13KB
- d852840dex991.htm (EX-99.1) — 11KB
- 0001193125-24-163398.txt ( ) — 799KB
- asmb-20240616.xsd (EX-101.SCH) — 3KB
- asmb-20240616_lab.xml (EX-101.LAB) — 18KB
- asmb-20240616_pre.xml (EX-101.PRE) — 11KB
- d852840d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 4.1 Registered Warrant. 4.2 Private Placement Warrant. 5.1 Opinion of Skadden, Arps, Slate, Meagher & Flom LLP. 10.1 Securities Purchase Agreement, dated June 16, 2024, by and between the Company and the Purchaser. 10.2 Securities Purchase Agreement, dated June 17, 2024, by and between the Company and Gilead Sciences, Inc. 10.3 Amendment No. 1 to Common Stock Purchase Agreement, by and between the Company and Gilead Sciences, Inc. 10.4 Amendment No. 1 to Investor Rights Agreement, by and between the Company and Gilead Sciences, Inc. 23.1 Consent of Skadden, Arps, Slate, Meagher & Flom LLP (included in Exhibit 5.1). 99.1 Press Release dated June 17, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Assembly Biosciences, Inc. Date: June 18, 2024 By: /s/ John O. Gunderson John O. Gunderson VP, General Counsel and Corporate Secretary 4